SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-22-010483
Filing Date
2022-05-02
Accepted
2022-05-02 16:55:01
Documents
11
Period of Report
2022-06-08

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A urgn20220426_def14a.htm DEF 14A 1276721
2 liz01.jpg GRAPHIC 3173
3 proxycardpg1.jpg GRAPHIC 152307
4 proxycardpg2.jpg GRAPHIC 118072
5 urogen01.jpg GRAPHIC 9078
6 urogen02.jpg GRAPHIC 36585
7 urogen03.jpg GRAPHIC 32218
8 urogen04.jpg GRAPHIC 5929
9 urogen05.jpg GRAPHIC 5643
10 urogen06.jpg GRAPHIC 5362
11 urogen07.jpg GRAPHIC 27619
  Complete submission text file 0001437749-22-010483.txt   1813276
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38079 | Film No.: 22882866
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences